Patents by Inventor Longcheng Wang

Longcheng Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190112312
    Abstract: Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 18, 2018
    Publication date: April 18, 2019
    Applicant: Pharmacyclics LLC
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia
  • Publication number: 20180194762
    Abstract: Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 12, 2018
    Inventors: Gordana B. Atallah, Wei Chen, Dimitry Khrakovsky, Longcheng Wang, Zhaozhong Jon Jia, Felix DeAnda, JR.
  • Patent number: 9862722
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: July 28, 2015
    Date of Patent: January 9, 2018
    Assignee: Pharmacyclics LLC
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody, Longcheng Wang
  • Patent number: 9708326
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 18, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Shunqi Yan, David J. Loury, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Longcheng Wang
  • Patent number: 9624224
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: April 18, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia, David J. Loury
  • Patent number: 9580416
    Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk) having the structure of Formula (B): Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: February 28, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Shunqi Yan, David J. Loury, Zhaozhong J. Jia, Leah Lynn Frye, Jeremy Robert Greenwood, Mee Yoo Shelley, Gordana Babic Atallah, Riccardo Zanaletti, Maria Pia Catalani, Luca Francesco Raveglia
  • Publication number: 20170050970
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 23, 2017
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia, David J. Loury
  • Publication number: 20170015671
    Abstract: Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 16, 2016
    Publication date: January 19, 2017
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia
  • Patent number: 9540385
    Abstract: Disclosed herein are pyrrolo[2,3-d]pyrimidine compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 10, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Longcheng Wang
  • Patent number: 9533991
    Abstract: Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: January 3, 2017
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia
  • Publication number: 20160375026
    Abstract: Disclosed herein are methods of using pyrrolo[2,3-d]pyrimidine Btk inhibitors, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, and inflammatory diseases or conditions.
    Type: Application
    Filed: September 9, 2016
    Publication date: December 29, 2016
    Inventors: Wei Chen, David J. Loury, Longcheng Wang
  • Publication number: 20160368924
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 1, 2016
    Publication date: December 22, 2016
    Inventors: Wei Chen, David J. Loury, Shunqi Yan, Longcheng Wang, Leah L. Frye
  • Patent number: 9469642
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: October 18, 2016
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Shunqi Yan, Longcheng Wang, Leah Lynn Frye
  • Publication number: 20160031891
    Abstract: Disclosed herein are amido compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 31, 2015
    Publication date: February 4, 2016
    Inventors: Wei Chen, Longcheng Wang, Zhaozhong J. Jia
  • Publication number: 20160002241
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: February 20, 2014
    Publication date: January 7, 2016
    Applicant: PHARMACYCLICS, LLC.
    Inventors: Wei CHEN, Shunqi YAN, David J. LOURY, Leah Lynn FRYE, Jeremy Robert GREENWOOD, Mee Yoo SHELLEY, Longcheng WANG
  • Publication number: 20160002225
    Abstract: Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: July 2, 2015
    Publication date: January 7, 2016
    Inventors: Wei CHEN, Longcheng WANG, Shunqi YAN, David J. LOURY, Zhaozhong J. JIA, Leah Lynn FRYE, Jeremy Robert GREENWOOD, Mee Yoo SHELLEY, Gordana Babic ATALLAH, Riccardo ZANALETTI, Maria Pia CATALANI, Luca Francesco RAVEGLIA
  • Publication number: 20150329550
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Application
    Filed: July 28, 2015
    Publication date: November 19, 2015
    Inventors: Wei CHEN, David J. LOURY, Tarak D. MODY, Longcheng WANG
  • Patent number: 9138436
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: September 22, 2015
    Assignee: PHARMACYCLICS LLC
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody, Longcheng Wang
  • Publication number: 20150239897
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Inventors: Wei CHEN, David J. LOURY, Longcheng WANG
  • Patent number: 9096604
    Abstract: Disclosed herein are compounds exemplified by the following structure Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds of Formula (I). Methods of using the Btk inhibitors exemplified by the structure of Formula (I) are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: August 4, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Wei Chen, David J. Loury, Longcheng Wang